Compare Davita Inc (DVA) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Davita Inc trades at $231.61 (market cap $14.92B), while YieldMax MSTR Option Income Strategy ETF trades at $13. The key difference: Davita Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| DVA | MSTY | |
|---|---|---|
Market Cap | $14.92B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $235.71 | $114.30 |
52-Week Low | $103.87 | $11.55 |
Enterprise Value | $27.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
MSTY trades at $12.57, down 2.03% with bearish technical signals from moving averages. The ETF maintains aggressive weekly dividend distributions, though recent coverage highlights concerns about return of capital and NAV erosion. Technical indicators show RSI in neutral territory while moving averages signal continued downward pressure.
The outlook remains challenging with structural risks to the covered-call strategy capping upside potential while exposing investors to full downside. Recent analyst commentary emphasizes unsustainable yield dynamics and dependence on Bitcoin volatility. Investment requires careful consideration of distribution sustainability versus capital preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
